ISLH-SASH Joint Webinar: Haematological, Haemostasis and Immune Aspects of SARS-COV-2 Infection

Speaker

Catherine Hayward, MD, PhD, FRCPC
Andreas Greinacher, MD
Tracey Wiggill, MD

Haematological, Haemostasis and Immune Aspects of SARS-COV-2 Infection

"Acquired Acute Coagulation Disorders Including COVID-19" Catherine Hayward, MD, PhD, FRCPC

"Detection of Platelet Activating Antibodies in Vaccine Associated Thrombotic Thrombocytopenia" Andreas Greinacher, MD

"COVID- 19 Molecular Mimicry, Auto-immunity and Haematological Findings." Tracey Wiggill, MD

Watch the Webinar


Answers to Questions from Live Webinar

Please check back for the Q&A.





Answers to Questions from Live Webinar

Below is a list of questions received from the live webinar attendees. Click on any question to reveal the speaker's response.

NEW QUESTION/ANSWER

It is common to see necrosis in cHL, hard to put a number on it offhand.

NEW QUESTION/ANSWER

Classic in the 2017 WHO

NEW QUESTION/ANSWER

It can be expressed in both CHL and ALCL so it may not be reliable.

NEW QUESTION/ANSWER

CD15, CD30, CD20, PAX5, OCT2, BOB1 and CD45 can be helpful.

NEW QUESTION/ANSWER

I have never seen this.

NEW QUESTION/ANSWER

No, there is no clinical role for this at present.

NEW QUESTION/ANSWER

This would be highly unusual

NEW QUESTION/ANSWER

I don’t have any experience with J chain but is usually negative in RS-cells. MUM1 is typically positive but not specific.

NEW QUESTION/ANSWER

No

NEW QUESTION/ANSWER

Yes. J-chain and MEF2B have been reported to be useful as well. PMID: 28851661

NEW QUESTION/ANSWER

I don’t think it is particularly helpful, some cases of cHL may have rearranged IGH

NEW QUESTION/ANSWER

No

NEW QUESTION/ANSWER

I don’t find it that helpful

NEW QUESTION/ANSWER

There has been some data to suggest it is prognostic.

NEW QUESTION/ANSWER

It does not appear to commonly result in loss of CD30 expression in follow-up biopsy but I don’t believe this has been extensively studied.

NEW QUESTION/ANSWER

Yes, for T-cell lymphomas including cutaneous T-cell lymphomas it is reasonable to report the % positive tumor cells because some trials that resulted in the approval of brentuximab used specific cutoffs.